European journal of neurologyHumansLevodopaParkinson DiseaseAntiparkinson AgentsCarbidopa
Subcutaneous Levodopa in Parkinson's Disease: A Systematic Review and Meta-Analysis.
Matthew Burton, Duncan Marsden, Dhruv Harish, Peter Morris, Carl Heneghan, Ailsa Butler, David Nunan
Published: 202610.1111/ene.70506
Abstract
BACKGROUND: Many Parkinson's disease patients receiving oral levodopa/carbidopa experience a troublesome wearing off effect. Higher doses to mitigate OFF-time are limited by adverse effects occurring at peak dopamine levels, particularly dyskinesia.…
Preview only. Read the full abstract at the source